With respect to clinical response, what is the trigger for using a different MOA -- including IL-6 inhibition -- in a patient who has failed a TNFI?

With respect to clinical response, what is the trigger for using a different MOA -- including IL-6 inhibition -- in a patient who has failed a TNFI?

With respect to clinical response, what is the trigger for using a different MOA — including IL-6 inhibition — in a patient who has failed a TNFI?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

William Shergy, MD

William Shergy, MD

Associate Clinical Professor of Medicine
University of Alabama at Birmingham
School of Medicine
Huntsville, Alabama
Assistant Consulting Professor of Medicine
Duke University Medical Center
Durham, North Carolina